Expression of the hypoxically regulated angiogenic factor adrenomedullin correlates with uterine leiomyoma vascular density.
Uterine leiomyomas are the most prevalent benign tumor type in women of reproductive age and are one of the most common indications for hysterectomy. The expression of five angiogenic factors, adrenomedullin (ADM), vascular endothelial growth factor (VEGF), acidic fibroblast growth factor, basic fibroblast growth factor, and platelet-derived endothelial cell growth factor/thymidine phosphorylase, were examined in 91 uteri collected throughout the menstrual cycle; 52 of which contained leiomyomata, and the remainder were normal controls. The microvascular density and endothelial proliferative indices were then determined for each of the uterine sections. ADM and VEGF were the most widely expressed angiogenic factors in the leiomyomas. Furthermore, the expression of ADM and VEGF in the endometrium and myometrium was up-regulated in leiomyoma-bearing uteri compared with controls. Although acidic fibroblast growth factor and basic fibroblast growth factor were expressed in leiomyomas and endometrium in all of the uterine samples examined, they were only expressed in the myometrium of leiomyomata-bearing uteri. Endothelial proliferation in leiomyomas was statistically greater than that of the myometrium and endometrium, both within and between uteri (P < 0.05). The vascular density in the myometrium but not the endometrium was significantly increased in leiomyoma-containing uteri (P < 0.05). Expression of ADM alone correlated directly with vascular density and endothelial cell proliferation index in leiomyomas and myometrium and may account for the high vascularity found in leiomyomas and the myometrium of leiomyoma-bearing uteri. As such, ADM is identified as a novel target for antiangiogenic therapy of these benign, clinically problematic uterine tumors.
Hague
S
S
Nuffield Department of Obstetrics and Gynecology, University of Oxford, John Radcliffe Hospital, United Kingdom.
Zhang
L
L
Oehler
M K
MK
Manek
S
S
MacKenzie
I Z
IZ
Bicknell
R
R
Rees
M C
MC
D053607:Adrenomedullin; D000328:Adult; D015415:Biomarkers / Q000032:analysis; D016228:Endothelial Growth Factors / Q000032:analysis; D004730:Endothelium, Vascular / Q000473:pathology; D005260:Female; D016220:Fibroblast Growth Factor 1 / Q000032:analysis; D016222:Fibroblast Growth Factor 2 / Q000032:analysis; D006801:Humans; D007889:Leiomyoma / Q000098:blood supply* / Q000473:pathology*; D008222:Lymphokines / Q000032:analysis; D008597:Menstrual Cycle; D008833:Microcirculation / Q000473:pathology*; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000473:pathology*; D018919:Neovascularization, Physiologic; D010455:Peptides / Q000032:analysis*; D012189:Retrospective Studies; D013939:Thymidine Phosphorylase / Q000032:analysis; D014594:Uterine Neoplasms / Q000098:blood supply* / Q000473:pathology*; D014599:Uterus / Q000098:blood supply* / Q000166:cytology / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D015415:Biomarkers; D016228:Endothelial Growth Factors; D008222:Lymphokines; D010455:Peptides; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D016220:Fibroblast Growth Factor 1; D053607:Adrenomedullin; D013939:Thymidine Phosphorylase